2020年全球肝癌和胆囊癌发病死亡分析

肝癌电子杂志 ›› 2022, Vol. 9 ›› Issue (4): 46-51.

2020年全球肝癌和胆囊癌发病死亡分析

单天昊¹, 安澜¹, 徐梦圆¹, 曾红梅^1,*, 蔡建强^2,*

1.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤登记办公室,北京 100021;
2.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肝胆外科,北京 100021

收稿日期:2022-03-31 出版日期:2022-12-31 发布日期:2023-02-03
通讯作者: ^* 蔡建强,E-mail：caijianqiang@cicams.ac.cn;曾红梅,E-mail：hongmeizeng@cicams.ac.cn
作者简介:单天昊,国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院,肿瘤登记办公室

Global liver cancer and gallbladder cancer incidence and mortality in 2020

Shan Tianhao, An Lan, Xu Mengyuan, Zeng Hongmei, Cai Jianqiang

1. Office of National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
2. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2022-03-31 Online:2022-12-31 Published:2023-02-03

摘要/Abstract

摘要： 目的：依据GLOBOCAN 2020数据比较2020年全球和中国肝癌和胆囊癌发病死亡负担,为癌症防控提供参考。
方法：依据国际癌症研究机构发布的2020年全球各国肝癌和胆囊癌发病死亡数据,比较其在不同地区、不同性别及年龄别间的差异。
结果：2020年全球新发肝癌病例905 677例,因肝癌死亡病例830 180例,标化发病率和标化死亡率分别为9.5/10万和8.7/10万;2020年全球新发胆囊癌病例115 949例,因胆囊癌死亡病例84 695例,标化发病率和标化死亡率分别为1.2/10万和0.84/10万。2020年全球肝癌标化发病率前5位的国家为蒙古、埃及、老挝、柬埔寨和越南;全球胆囊癌标化发病率前5位的国家为玻利维亚、智利、孟加拉国、尼泊尔和韩国。2020年中国新发肝癌病例410 038例,标化发病率为18.2/10万,标化发病率居全球第8位;因肝癌死亡病例391 152例,标化死亡率为17.2/10万。2020年中国新发胆囊癌病例28 923例,标化发病率为1.2/10万,标化发病率居全球第39位;因胆囊癌死亡病例23 297例,标化死亡率为0.97/10万。
结论：肝癌和胆囊癌发病死亡负担在不同国家和人群间存在差异,应根据不同人群的发病死亡特点制订相应防控策略。

关键词: 肝癌, 胆囊癌, 发病率, 死亡率, 全球

Abstract: Objective:According to the data of GLOBOCAN 2020, we compared the global and Chinese incidence and mortality of liver cancer and gallbladder cancer in 2020, to provide a scientific basis for cancer prevention and control.
Method:According to the incidence and mortality data of liver cancer and gallbladder cancer released by the International Agency for Research on Cancer in 2020, the differences among different regions, genders and ages were compared.
Result:In 2020, there were 905 677 new cases and 830 180 deaths of liver cancer globally, with age-standardized incidence and mortality rates of 9.5/100 000 and 8.7/100 000, respectively. For gallbladder cancer, the numbers of new cases and deaths were 115 949 and 84 695, respectively, with the age-standardized incidence and mortality of 1.2/100 000 and 0.84/100 000, respectively. The top five countries with highest incidence of liver cancer were Mongolia, Egypt, Laos, Cambodia and Vietnam. The top five countries with highest incidence of gallbladder cancer were Bolivia, Chile, Bangladesh, Nepal and Korea. In 2020, there were 410 038 new cases of liver cancer in China, with a standardized incidence rate of 18.2/100 000, ranking 8th among all countries. There were 391 152 new cases of death from liver cancer in China, with an age-standardized mortality rate of 17.2/100 000. For gallbladder cancer, there were 28 923 new cases of incidence in China, with an age-standardized incidence rate of 1.2/100 000, ranking 39th among all countries. There were 23 297 new cases of death from gallbladder cancer in China, with an age-standardized mortality rate of 0.97/100 000.
Conclusion:The disease burden of liver cancer and gallbladder cancer is different between countries. Different prevention and control strategies should be formulated according to different populations.

Key words: Liver cancer, Gallbladder cancer, Incidence, Mortality, World

单天昊, 安澜, 徐梦圆, 曾红梅, 蔡建强. 2020年全球肝癌和胆囊癌发病死亡分析[J]. 肝癌电子杂志, 2022, 9(4): 46-51.

Shan Tianhao¹, An Lan¹, Xu Mengyuan¹, Zeng Hongmei^1,*, Cai Jianqiang^2,*. Global liver cancer and gallbladder cancer incidence and mortality in 2020[J]. Electronic Journal of Liver Tumor, 2022, 9(4): 46-51.

参考文献

[1] ZENG H, CHEN W, ZHENG R, et al.Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[2] ALLEMANI C, MATSUDA T, CARLO V D, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
[3] BERTRAN E, HEISE K, ANDIA M E, et al.Gallbladder cancer: incidence and survival in a high-risk area of Chile[J]. Int J Cancer, 2010, 127(10): 2446-2454.
[4] BRAY F, GUILLOUX A, SANKILA R, et al.Practical implications of imposing a new world standard population[J]. Cancer Causes Control, 2002, 13(2): 175-182.
[5] YANG J, HAINAUT P, GORES G, et al.A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019 ,16(10): 589-604.
[6] GLOBAL BURDEN OF DISEASE LIVER CANCER COLLABORATION; AKINYEMIJU T ABERA S,et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691.
[7] LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27(47): 6550-6557.
[8] 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10): 721-727.
[9] CHEN W, XIA C, ZHENG R, et al.Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment[J]. Lancet Glob Health, 2019, 7(2): e257-e269.
[10] CHIMED T, SANDAGDORJ T, ZNAOR A, et al.Cancer incidence and cancer control in Mongolia: Results from the National Cancer Registry 2008-12[J]. Int J Cancer, 2017, 140(2): 302-309.
[11] MOHAMOUD Y A, MUMTAZ G R, RIOME S, et al.The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis[J]. BMC Infect Dis, 2013, 13: 288.
[12] JAFRI W, KAMRAN M.Hepatocellular Carcinoma in Asia: A Challenging Situation[J]. Euroasian J Hepatogastroenterol, 2019, 9(1): 27-33.
[13] SUNG H, FERLAY J, SIEGEL R L, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[14] LUO Z, LI L, RUAN B.Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period[J]. Int J Infect Dis, 2012, 16(2): e82-e88.
[15] 王富珍, 张国民, 沈立萍, 等. 1992和2014年中国不同流行地区1~29岁人群乙型肝炎血清流行病学调查结果对比分析[J]. 中华预防医学杂志, 2017, 51(6): 462-468.
[16] AN L, ZHENG R, ZHANG S, et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between2006 and 2015 in China: estimates based on data from 188 population-based cancer registries[J]. Hepatobil Surg Nutr, 2021:
[17] VALLE J W, KELLEY R K, NERVI B, et al.Biliary tract cancer[J]. Lancet, 2021, 397(10272): 428-444.
[18] BAIU I, VISSER B.Gallbladder Cancer[J]. JAMA, 2018, 320(12): 1294.
[19] PARK M, SONG D Y, JE Y, et al.Body mass index and biliary tract disease: a systematic review and meta-analysis of prospective studies[J]. Prev Med, 2014, 65: 13-22.
[20] AERTS R, PENNINCKX F. The burden of gallstone disease in Europe[J]. Aliment Pharmacol Ther, 2003, 18 Suppl 3: 49-53.
[21] LAMMERT F, GURUSAMY K, KO C W, et al.Gallstones[J]. Nat Rev Dis Primers, 2016, 2: 16024.
[22] RENEHAN A G, TYSON M, EGGER M, et al.Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies[J]. Lancet, 2008, 371(9612): 569-578.
[23] 徐建庆, 陈晨, 宋虎伟, 等. 胆囊癌发病相关危险因素分析[J]. 中国普通外科杂志, 2015, 24(2): 190-194.
[24] ROCK C L, THOMSON C, GANSLER T, et al.American Cancer Society guideline for diet and physical activity for cancer prevention[J]. CA Cancer J Clin, 2020, 70(4): 245-271.
[25] CARIATI A, PIROMALLI E, CETTA F.Gallbladder cancers: associated conditions, histological types, prognosis, and prevention[J]. Eur J Gastroenterol Hepatol, 2014, 26(5): 562-569.
[26] FLEGAL K M, KRUSZON-MORAN D, CARROLL M D, et al.Trends in Obesity Among Adults in the United States, 2005 to 2014[J]. JAMA, 2016, 315(21): 2284-2291.
[27] STANAWAY J D, FLAXMAN A D, NAGHAVI M, et al.The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013[J]. Lancet, 2016, 388(10049): 1081-1088.